EUVIMEDEUVIMED entdecken
Crossref

Clinicopathologic and Molecular Features of Tubo-Ovarian Carcinosarcomas With an Emphasis on p53 Wild-Type, KRAS-Mutated Tumors

Phoebe M Hammer, Leandra G Kingsley, Simone A Sasse, Brooke E Howitt

Modern Pathology · 2026-04 · 39 (4) · 100971

DOI: 10.1016/j.modpat.2026.100971 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2026-04. Verfasst von Phoebe M Hammer und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Stanford University School of Medicine, Stanford, California. Hauptthemen laut MEDLINE: Carcinosarcoma, Ovarian Neoplasms, Proto-Oncogene Proteins p21(ras), Tumor Suppressor Protein p53. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Stanford University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tubo-ovarian carcinosarcomas (OCS) are uncommon, aggressive tumors. Recent literature in uterine carcinosarcomas has shown prognostic differences by the molecular classification established by The Cancer Genome Atlas. Our aim was to delineate the molecular subtypes within OCS and associated clinicopathologic, immunohistochemical, and additional molecular features. A total of 57 OCS were identified at our institution. The overall median follow-up period was 32.3 months, and 5-year survival rates were 71% (stage I/II), 42% (stage III), and 17% (stage IV). Fifty-one (89%) tumors were of the p53-abnormal molecular subtype. Five (9%) tumors were of no specific molecular subtype, and all 5 of these tumors harbored canonical mutations in KRAS (codon 12). We also identified the first reported primary POLE-mutated OCS in a patient with Lynch syndrome; this case was assigned as of a double-classifier POLE-mutated/mismatch repair-deficient molecular subtype. No tumors were of the single-classifier mismatch repair-deficient or POLE-mutated molecular subtype. Compared with the p53-abnormal tumors, KRAS-mutated tumors occurred in younger women at lower stages, but did recur in 2 out of 5 (40%) patients. They always showed endometrioid rather than high-grade serous morphology and were usually ER, PR, and WT1 negative. Three KRAS-mutated tumors also had at least focal mesonephric-like histology. Although rare, p53 wild-type tumors represent a small subset of OCS that show distinct clinical and histologic features and are largely driven by KRAS mutations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarcinosarcomaOvarian NeoplasmsProto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53Biomarkers, TumorFallopian Tube NeoplasmsHumansFemaleMutationAgedMiddle AgedAged, 80 and overAdultImmunohistochemistryDNA Mutational Analysis

Stichwörter der Autor:innen

KRASPOLEcarcinosarcomamolecular classificationovarian cancerovarian carcinosarcoma

Substanzen

Proto-Oncogene Proteins p21(ras)Tumor Suppressor Protein p53KRAS protein, humanBiomarkers, TumorTP53 protein, human

Autor:innen und Institutionen

  • Department of Pathology, Stanford University School of Medicine, Stanford, California.
  • Division of Gynecologic Oncology, Stanford University School of Medicine, Stanford, California.
  • Department of Pathology, Stanford University School of Medicine, Stanford, California. Electronic address: bhowitt@stanford.edu.

Förderung

  • Stanford University

Zitieren

APA

Hammer, P. M., Kingsley, L. G., Sasse, S. A., & Howitt, B. E. (2026). Clinicopathologic and Molecular Features of Tubo-Ovarian Carcinosarcomas With an Emphasis on p53 Wild-Type, KRAS-Mutated Tumors. Modern Pathology, 39(4), 100971. https://doi.org/10.1016/j.modpat.2026.100971

Vancouver

Hammer PM, Kingsley LG, Sasse SA, Howitt BE. Clinicopathologic and Molecular Features of Tubo-Ovarian Carcinosarcomas With an Emphasis on p53 Wild-Type, KRAS-Mutated Tumors. Modern Pathology. 2026;39(4):100971. doi:10.1016/j.modpat.2026.100971

BibTeX
@article{Hammer2026,
  author = {Hammer, Phoebe M and Kingsley, Leandra G and Sasse, Simone A and Howitt, Brooke E},
  title = {Clinicopathologic and Molecular Features of Tubo-Ovarian Carcinosarcomas With an Emphasis on p53 Wild-Type, KRAS-Mutated Tumors},
  journal = {Modern Pathology},
  year = {2026},
  volume = {39},
  number = {4},
  pages = {100971},
  doi = {10.1016/j.modpat.2026.100971}
}
Kostenlos starten →